Paratek Pharmaceuticals, Inc. is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on PRTK’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Paratek Pharmaceuticals could be a solid choice for investors.
Current Quarter Estimates for PRTK
In the past 30 days, 2 estimates have gone higher for Paratek Pharmaceuticals while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates rising from a loss of $1.25 a share 30 days ago, to a loss of $1.20 per share today, a move of 4.2%.
Current Year Estimates for PRTK
Meanwhile, Paratek Pharmaceuticals’ current year figures are also looking quite promising, with 4 estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, rising from a loss of $4.69 per share 30 days ago to a loss of $4.22 per share today, an increase of 11.1%.
Paratek Pharmaceuticals, Inc. Price and Consensus
Bottom Line
The stock has also started to move higher lately, adding 33.5% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Trades Could Profit ""Big-League"" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Image: Bigstock
Why Paratek Pharmaceuticals (PRTK) Could Be Positioned for a Surge?
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on PRTK’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Paratek Pharmaceuticals could be a solid choice for investors.
Current Quarter Estimates for PRTK
In the past 30 days, 2 estimates have gone higher for Paratek Pharmaceuticals while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates rising from a loss of $1.25 a share 30 days ago, to a loss of $1.20 per share today, a move of 4.2%.
Current Year Estimates for PRTK
Meanwhile, Paratek Pharmaceuticals’ current year figures are also looking quite promising, with 4 estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, rising from a loss of $4.69 per share 30 days ago to a loss of $4.22 per share today, an increase of 11.1%.
Paratek Pharmaceuticals, Inc. Price and Consensus
Paratek Pharmaceuticals, Inc. Price and Consensus | Paratek Pharmaceuticals, Inc. Quote
Bottom Line
The stock has also started to move higher lately, adding 33.5% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Trades Could Profit ""Big-League"" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>